In summary, our study raises the possibility that in selected patients, a short‐acting GLP‐1 receptor agonist could be a useful adjunctive treatment in T1D to limit post‐prandial glucose rise. The gene discussed is GLP1R; the disease is type 1 diabetes mellitus.